Evolus reports Q3 2026 revenue up 13%, reaffirms 2026 and 2028 outlooks
Evolus posted a fourth straight quarter of positive adjusted EBITDA and said it still expects FDA approval of Evolysse Sculpt by year-end 2026.
Evolus, Inc. announced third quarter 2026 financial results on November 4, 2026. Total net revenues for the third quarter of 2026 were $78.0 million, a 13% increase over the third quarter of 2025.1 Net revenue included $70.1 million of global toxin revenue and $7.9 million of revenue from injectable hyaluronic acid (HA) gels.1
On the pipeline, the company continued advancing Evolysse Sculpt through the FDA review process and said it remains focused on bringing the product to market.1 Guidance reflects no revenue contribution from Evolysse Sculpt, which is anticipated to receive U.S. approval in the fourth quarter of 2026.1
Evolus also disclosed new business development activity. In October the company entered into an option agreement for an early-stage, potentially first-in-class, sustained-release injectable aesthetic procedure for hair growth, which provides capital-efficient entry into a new category, lets Evolus evaluate human clinical data before a larger investment decision, and does not impact its existing financial outlook.1 In July the company entered into an exclusive licensing, supply, and distribution agreement with IBSA to develop and commercialize Profhilo in the United States.1 In August it signed an exclusive licensing agreement with Symatese to commercialize the Estyme collection in Canada, Australia, and New Zealand.1
On tariffs, following recent guidance from the Commerce Department, the company does not expect Jeuveau to be subject to tariffs, while Evolysse, classified as a medical device and imported from France, remains subject to a 10% tariff.1
On cash, as of September 30, 2026, Evolus held $41.7 million of cash and cash equivalents, compared with $45.2 million as of June 30, 2026, and had access to approximately $120 million of additional non-dilutive capacity.1 The company said it expects these resources to provide sufficient liquidity to execute its operating plan and strategic priorities.1
The company reaffirmed full-year 2026 total net revenue guidance of $330 million to $337 million and its 2028 long-term outlook of $450 million to $500 million in total net revenue, with Adjusted EBITDA margins of 13% to 15% for 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.